In Billing
Oct 15th, 2010
Effective for claims with service dates on or after Aug. 4, Medicare will nationally cover the use of allogenic hematopoietic stem cell transplantation (HSCT) for myelodysplastic syndrome (MDS) when provided in a Medicare-approved clinical study under Coverage Evidence Development (CED). In all other settings, HSCT for MDS is nationally non-covered by Medicare. MDS refers to ...
In CMS
Nov 16th, 2009
The Centers for Medicare & Medicaid Services (CMS) has initiated a national coverage analysis (NCA) for the use of allogeneic hematopoietic stem cell transplantation (HSCT) for Medicare patients with myelodysplastic syndrome (MDS). MDS refers to a heterogeneous group of acquired bone marrow disorders characterized by dysplastic growth of hematopoietic progenitors and a hypercellular bone marrow...
In CMS
Jun 29th, 2009
Noridian Administrative Services has clarified its coverage policy for chemotherapeutic drugs that may cause chemotherapy-induced anemia. Coverage Update: ESA Therapy for Drug-induced Anemia was last modified: July 5th, 2011 by admin aapc...
In Billing
Apr 27th, 2009
Effective April 1, a policy change mandated in the 2009 Medicare Physician Fee Schedule (MPFS) final rule (FR Doc E8-26213) shortens the time physicians and nonphysician practioners (NPPs) have to retroactively bill for services after successful enrollment into the Medicare program from 27 months to 30 days. The policy change also gives physicians only 30 ...